Caris Life Sciences has recalled one unit of its MI Cancer Seek assay because it provided an incorrect test result, leading to a wrong drug therapy recommendation. The MI Cancer Seek is a laboratory test used by doctors to analyze cancer tumors and determine the most effective treatment for patients. While only one unit is affected, this specific error could result in a patient receiving an ineffective or harmful medication based on flawed genetic data. Laboratory professionals should contact the manufacturer immediately to return or correct the device.
Incorrect test results from this assay can cause doctors to prescribe the wrong cancer treatment, potentially leading to treatment failure or unnecessary side effects. One instance of an incorrect drug therapy recommendation has already occurred.
Single-site assay for tumor mutational profiling.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.